Roberts MS, Rowland M.A dispersion model of hepatic elimination: 3. Application to
metabolite formation and elimination kinetics. J Pharmacokinet Biopharm 1986c;14:
289–308.
Rowland M, Benet LZ, Graham GG. Clearance concepts in pharmacokinetics. J
Pharmacokinet Biopharm 1:1973;123–136.
Satoh T, Hosokawa M. The mammalian carboxylesterases: from molecules to
functions. Annu Rev Pharmacol Toxicol 1998;38:257–288.
Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN. Current
progress on esterases: from molecular structure to function. Drug Metab Dispos
30:2002;488–493.
Seddon T, Michelle I, Chenery RJ. Comparative drug metabolism of diazepam in
hepatocytes isolated from man, rat, monkey and dog. Biochem Pharmacol
1989;38:1657–1665.
Shen M, Xiao Y, Golbraikh A, Gombar VK, Tropsha A. Development and validation
of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. J Med
Chem 2003;46:3013–3020.
Shibata Y, Takahashi H, Ishii Y.A convenientin vitroscreening method for predicting
in vivodrug metabolic clearance using isolated hepatocytes suspended in serum. Drug
Metab Dispos 2000;28:1518–1523.
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual
variations in human liver cytochrome P-450 enzymes involved in the oxidation of
drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese
and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414–423.
Shou M, Lin Y, Lu P, Tang C, Mei Q, Cui D, Tang W, Ngui JS, Lin CC, Singh R,
Wong BK, Yergey JA, Lin JH, Pearson PG, Baillie TA, Rodrigues AD, Rushmore
TH.Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab
2001;2:17–36.
Skopp G, Klingmann A, Potsch L, Mattern R.In vitrostability of cocaine in whole
blood and plasma including ecgonine as a target analyte. Ther Drug Monit
2001;23:174–181.
Slaughter D, Takenaga N, Lu P, Assang C, Walsh DJ, Arison BH, Cui D, Halpin RA,
Geer LA, Vyas KP, Baillie TA.Metabolism of rofecoxibin vitrousing human liver
subcellular fractions. Drug Metab Dispos 2003;31:1398–1408.
Smith DA, van de Waterbeemd H.Pharmacokinetics and metabolism in early drug
discovery. Curr Opin Chem Biol 1999;3:373–378.
Smith RL, Timbrell JA.Factors affecting the metabolism of phenacetin. I. Influence of
dose, chronic dosage, route of administration and species on the metabolism of
(1-14C-acetyl)phenacetin. Xenobiotica 1974;4:489–501.
Soars MG, Burchell B, Riley RJ.In vitroanalysis of human drug glucuronidation and
prediction ofin vivometabolic clearance. J Pharmacol Exp Ther 2002;301:382–390.
Sugie M, Asakura E, Zhao YL, Torita S, Nadai M, Baba K, Kitaichi K, Takagi K,
Takagi K, Hasegawa T.Possible involvement of the drug transporters P-glycoprotein
and multidrug resistance-associated protein Mrp2 in disposition of azithromycin.
Antimicrob Agents Chemother 2004;48:809–814.
Takahashi H, Kashima T, Kimura S, Muramoto N, Nakahata H, Kubo S, Shimoyama
Y, Kajiwara M, Echizen H.Determination of unbound warfarin enantiomers in
REFERENCES 445